Company profile

Ticker
JNJ
Exchange
Website
CEO
Alex Gorsky
Employees
Incorporated
Location
Fiscal year end
Former names
JOHNSON & JOHNSON ET AL
SEC CIK
IRS number
221024240

JNJ stock data

(
)

Calendar

23 Oct 20
2 Dec 20
3 Jan 21

News

Quarter (USD) Sep 20 Jun 20 Mar 20 Sep 19
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD) Dec 19 Dec 18 Dec 17 Jan 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code 10b5-1 $Price #Shares $Value #Remaining
8 Sep 20 Weinberger Mark A Deferred Share Units Common Stock Grant Aquire A No 0 212.569 0 1,874.999
8 Sep 20 Washington A. Eugene Deferred Share Units Common Stock Grant Aquire A No 0 352.909 0 22,723.3
8 Sep 20 Marillyn A Hewson Deferred Share Units Common Stock Grant Aquire A No 0 212.569 0 1,874.999
2 Sep 20 Kathryn E Wengel Common Stock Sell Dispose S No 153.527 8,238 1.26M 58,419.504
2 Sep 20 Kathryn E Wengel Common Stock Sell Dispose S No 153.508 7,877 1.21M 66,657.504
2 Sep 20 Kathryn E Wengel Common Stock Option exercise Aquire M No 65.37 7,877 514.92K 74,534.504
2 Sep 20 Kathryn E Wengel Common Stock Option exercise Aquire M No 62.2 8,238 512.4K 66,657.504
2 Sep 20 Kathryn E Wengel Employee Stock Options Common Stock Option exercise Dispose M No 65.37 7,877 514.92K 0
2 Sep 20 Kathryn E Wengel Employee Stock Options Common Stock Option exercise Dispose M No 62.2 8,238 512.4K 0
28 Jul 20 McEvoy Ashley Common Stock Sell Dispose S No 147.47 29,000 4.28M 21,681.502
67.0% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 2868 2901 -1.1%
Opened positions 108 155 -30.3%
Closed positions 141 114 +23.7%
Increased positions 1323 1311 +0.9%
Reduced positions 1138 1165 -2.3%
13F shares
Current Prev Q Change
Total value 2.4T 2.27T +5.8%
Total shares 1.76B 1.78B -1.0%
Total puts 13.05M 13.11M -0.5%
Total calls 11.64M 12.06M -3.5%
Total put/call ratio 1.1 1.1 +3.1%
Largest owners
Shares Value Change
Vanguard 228.98M $34.09B -1.2%
BLK Blackrock 193.75M $28.85B +0.0%
STT State Street 149.72M $22.29B -1.9%
Geode Capital Management 39.54M $5.88B -0.1%
State Farm Mutual Automobile Insurance 34.57M $5.15B 0.0%
BAC Bank Of America 34.53M $5.14B -0.4%
Wellington Management 33.77M $5.03B +17.4%
NTRS Northern Trust 33.69M $5.02B -0.8%
BK Bank Of New York Mellon 30.33M $4.52B +0.8%
Massachusetts Financial Services 29.45M $4.38B -0.5%
Largest transactions
Shares Bought/sold Change
Nordea Investment Management Ab 8.61M -8.61M -50.0%
Wellington Management 33.77M +5M +17.4%
STT State Street 149.72M -2.85M -1.9%
Vanguard 228.98M -2.76M -1.2%
GS Goldman Sachs 10.27M -1.79M -14.8%
STRS Ohio 0 -1.59M EXIT
BEN Franklin Resources 13.92M +1.58M +12.8%
Independent Franchise Partners 3.71M -1.45M -28.1%
Natixis 1.76M +1.32M +298.8%
Canada Pension Plan Investment Board 2.63M -1.27M -32.5%

Financial report summary

?
Risks
  • Global sales in the Company’s pharmaceutical and medical devices segments may be negatively impacted by healthcare reforms and increasing pricing pressures.
  • The Company is subject to significant legal proceedings that can result in significant expenses, fines and reputational damage.
  • Product reliability, safety and effectiveness concerns can have significant negative impacts on sales and results of operations, lead to litigation and cause reputational damage.
  • Changes in tax laws or exposures to additional tax liabilities could negatively impact the Company’s operating results.
  • The Company may not be able to successfully secure and defend intellectual property rights essential to the Company’s businesses.
  • The Company’s businesses operate in highly competitive product markets and competitive pressures could adversely affect the Company’s earnings.
  • Significant challenges or delays in the Company’s innovation and development of new products, technologies and indications could have an adverse impact on the Company’s long-term success.
  • The Company faces increasing regulatory scrutiny which imposes significant compliance costs and exposes the Company to government investigations, legal actions and penalties.
  • The Company faces a variety of risks associated with conducting business internationally.
  • Interruptions and delays in manufacturing operations could adversely affect the Company’s business, sales and reputation.
  • Counterfeit versions of our products could harm our patients and have a negative impact on our revenues, earnings, reputation and business.
  • An information security incident, including a cybersecurity breach, could have a negative impact to the Company’s business or reputation
Management Discussion
  • For discussion on results of operations and financial condition pertaining to the fiscal years 2018 and 2017 see the Company’s Annual Report on Form 10-K for the fiscal year ended December 30, 2018, Item 7. Management's Discussion and Analysis of Results of Operations and Financial Condition.
  • In 2019, worldwide sales increased 0.6% to $82.1 billion as compared to an increase of 6.7% in 2018. These sales changes consisted of the following:
  • The net impact of acquisitions and divestitures on the worldwide sales growth was a negative impact of 1.7% in 2019 and a positive impact of 0.8% in 2018.
Content analysis ?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
8th grade Avg
New words: abeyance, arguing, begun, channel, CONCERTA, deadline, enforcement, flat, Genmab, immaterial, LCC, learned, methylphenidate, Momenta, OGX, payer, PHS, progression, rebounding, renewed, senior, structured, tribal, TRINZA, unsecured, USCBP, withdrew
Removed: articulated, Aurobindo, commence, CYPHER, FZE, geometry, grant, Hetero, Indoco, leveraging, Medinol, Prinston, reconsider, reserve, Sun, Taro, unreasonably, vacate, valuation, willfully